VIVUS' (VVUS) Qsymia Prescription Insurer Pay Rate Rose 5% in Week Two
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
VIVUS (VVUS) Higher as Qsymia Prescriptions Show Confident Growth
October 9, 2012 1:04 PM EDTVIVUS, Inc. (Nasdaq: VVUS) is up again Tuesday following new Qsymia sales data.
According to Source Healthcare Analytics, as cited by Bloomberg Industries, about 57 percent of Qsymia prescriptions were for the lowest dose, with 40 percent for the medium... More
